Non-nucleoside reverse transcriptase inhibitors

A compound according to formula I

• wherein
• X1 is —O—;
• R1 and R2 are (i) each independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 sulfonyl, C1-6 haloalkoxy, C1-6 haloalkylthio, halogen, amino, alkylamino, dialkylamino, aminoacyl, nitro and cyano;
• or, (ii) together R1 and R2 are —O—CH═CH— or —O—CH2CH2— provided that R1 is not hydrogen;
• R3 and R4 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy C1-6 alkylthio, C1-6 haloalkylthio, halogen, amino, nitro and cyano;
• R5 is aryl substituted with one to three substituents independently selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —C≡CCH2OH, —C≡CCH2NMe2, C1-6 haloalkyl, C3-8 cycloalkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 sulfonyl, C1-6 haloalkoxy, C1-6 haloalkylthio, hydroxy, halogen, nitro and cyano, said alkyl and said cycloalkyl are optionally substituted with one or two substituents independently selected from the group consisting of alkyl, hydroxy, alkoxy, thiol, alkylthio, halogen, amino, alkylamino, dialkylamino, amino alkyl, alkylaminoalkyl, and dialkylamino;
• Ar is a substituted phenyl ring according to formula IIa with the proviso that R7a and R7c are not both hydrogen or if R7c is hydrogen, then R7a is chlorine:
• R7a is selected from the group consisting of hydrogen, C1-6 alkyl, C1-3 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, halogen and cyano;
• R7b in each incidence is independently selected from the group consisting of C1-6 haloalkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 sulfonyl, amino C1-6 alkylsulfonyl, SO2NR11aR11b, C1-6 haloalkoxy, C1-6 haloalkylthio, hydroxy, amino, C1-6 alkylamino, C1-6 dialkylamino, aminoacyl, acyl, CONR8R9, nitro, cyano, C1-6 heteroalkoxy, —X2(CH2)pS(O)2NR8R9, —X2(CH2)pNHC(O)NHR8R9, —X2(CH2)pS(O)2NR8R9 and —X2(CH2)pNHCOOR10;
• R7c is selected from the group consisting of C1-6 heteroalkoxy, —S(O)2NR8R9, —X2CH2(CH2)pS(O)2NR8R9;
• —X2(CH2)pNHC(O)NHR8R9, X6(CH2)vCONR8R9, —SO2R13, —NR8R9, X2(CH2)pNR11S(O)2NR8R9, —X2(CH2)pNHCOOR10, —X6(CH2)vCOOR10, —X6(CH2)vCN, —OR15 and C(═O)CH2N[(CH2)2]2X4;
• R8 and R9 (i) taken independently, one of R8 and R9 is hydrogen or C1-6 alkyl and the other of R8 and R9 is selected from the group consisting of hydrogen, —C(═O)R14, —C(═O)CR12NH2, —(CH2)2N[(CH2)2]2O, COCO2Me, C3-8 cycloalkyl said cycloalkyl optionally substituted with one or two hydroxyl substituents, pyranyl, C1-6 alkyl and aryl said alkyl and said aryl groups optionally substituted with one or two substituents independently selected from the group consisting of hydroxy, C1-6 alkoxy, thiol, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 sulfonyl, and halogen;
• or, (ii) R8 and R9 taken together are (CH2)2—X5—(CH2)2, —(CH2)o— or (CH2)rS(O)n— optionally substituted with one or two substituents selected from the group consisting of halogen, hydroxyl and NR11aR11b;
• R10 is C1-6 alkyl;
• R11 is hydrogen or C1-6 alkyl;
• R11a and R11b are independently R11;
• R12 is the sidechain of a naturally occurring α-amino acid;
• R13 is C1-6 alkyl;
• —(CH2)sCO2R11, —(CH2)2CN, —(CH2)2NH2, —(CH2)uOH;
• R14 is C1-10 alkyl, —(CH2)sNHR11aR11b, (CH2)sOR11, —CH2CH(OH)CH3, CH2N[(CH2)2]2O, —(CH2)2CO2R11, optionally substituted phenyl or pyridinyl;
• R15 is C1-6 alkyl substituted with one to three hydroxyl groups;
• X2 is —O— or a bond;
• X4 is —O— or —NMe-;
• X5 is —O—, —S(O)n— or NR11;
• X6 is O— or —S(O)n—;
• m is an integer from 0 to 2;
• n is an integer from 0 to 2;
• o is an integer from 4 to 6;
• p is an integer from 0 to 6;
• r is an integer from 3 to 4
• s is an integer from 1 to 2;
• u is an integer from 2 to 3;
• v is an integer from 2 to 6;
• and,
• hydrates, solvates, and acid addition salts or salts of the conjugate base thereof.